share_log

Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62

Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62

花旗集团以买入评级启动对Xenon Pharmicals的报道,宣布目标股价为62美元
Benzinga ·  01/04 04:47

Citigroup analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $62.

花旗集团分析师大卫·霍恩开始对Xenon Pharmicals(纳斯达克股票代码:XENE)进行报道,评级为买入,并宣布目标股价为62美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发